July 22, 2026 Exelixis Inc. Set to Announce Q2 2026 Financial Results: A Look Ahead Exelixis, Inc. is set to announce its Q2 2026 financial results on August 5, followed by a conference call at 5:00 p.m. ET. Investors will gain insights into the company's oncology innovations and performance.
June 22, 2026 Exelixis Inc. Releases Promising Updates on Phase 3 STELLAR-303 Trial for Zanzalintinib in Metastatic Colorectal Cancer Exelixis Inc. has released updates on the Phase 3 STELLAR-303 trial of zanzalintinib combined with atezolizumab for metastatic colorectal cancer. The final analysis shows a favorable survival trend in patients without active liver metastases, with a median overall survival of 15.9 months. The safety profile remains consistent with previous findings, and further research is anticipated.
May 27, 2026 Exelixis Inc. Set to Engage Investors with Upcoming Fireside Chats Exelixis, Inc. will present at two major healthcare conferences in June 2026, aiming to engage investors and showcase its oncology portfolio. Live webcasts will be available for those unable to attend.
May 21, 2026 Exelixis Highlights Innovative Cancer Therapies at 2026 ASCO Annual Meeting Exelixis will present pivotal findings on CABOMETYX and zanzalintinib at the ASCO 2026 Annual Meeting, highlighting advancements in cancer treatment strategies. Key studies include analyses from the CABINET and STELLAR-303 trials, showcasing the continued evolution of oncology care.
May 07, 2026 Exelixis Inc. to Host Fireside Chats at Major Investor Conferences in May Exelixis, Inc. will host fireside chats at four major investor conferences in May 2026 to discuss its oncology advancements and innovative product pipeline. These events emphasize the company’s commitment to investor engagement and transparency in cancer treatment.
May 05, 2026 Exelixis Reports Strong Q1 2026 Financial Results and Corporate Updates Exelixis, Inc. reported strong Q1 2026 earnings with revenues of $610.8M, driven by a rise in oncology product sales. The company is focused on expanding its pipeline and enhancing shareholder value through stock repurchase programs.
May 05, 2026 Exelixis Inc. Reports Strong Q1 2026 Financial Performance Exelixis Inc. reported strong financial performance in Q1 2026, with revenues increasing to $610.8 million and a focus on innovative oncology treatments. The company is advancing its product pipeline while managing costs effectively, despite regulatory challenges ahead.
April 21, 2026 Exelixis Inc. Announces Upcoming Q1 2026 Financial Results and Business Update Exelixis, Inc. is set to announce its Q1 2026 financial results on May 5, along with updates on its oncology product pipeline. A conference call will provide detailed insights for investors and stakeholders.
February 24, 2026 Exelixis to Engage Investors in March with Fireside Chats Exelixis, Inc. is set to host fireside chats at key investor conferences in March 2026, showcasing its advancements in cancer care and discussing its clinical pipeline. Investors can access the webcasts to gain insights into the company’s strategies and innovations.
February 10, 2026 Exelixis Inc. Reports Strong Financial Results for Q4 and Fiscal Year 2025 Exelixis, Inc. reported strong financial results for Q4 and the fiscal year 2025, highlighting a revenue growth driven by cabozantinib sales. The company anticipates a transformative 2026 with new strategic initiatives and clinical milestones.
February 10, 2026 Exelixis Inc. Reports Strong Financial Performance for 2025 Exelixis Inc. has reported significant financial growth for 2025, with total revenues reaching $2.32 billion and net income increasing to $783 million. The company continues to advance its oncology pipeline, facing regulatory challenges while focusing on delivering innovative cancer treatments.
February 02, 2026 Exelixis Advances Cancer Treatment with FDA Acceptance of Zanzalintinib NDA Exelixis has announced the FDA's acceptance of the NDA for zanzalintinib, a new treatment for metastatic colorectal cancer. Supported by the STELLAR-303 clinical trial, this therapy aims to address significant unmet needs in a population with limited treatment options and poor outcomes.
January 27, 2026 Exelixis Inc. Prepares to Release Fourth Quarter and Fiscal Year 2025 Financial Results Exelixis Inc. is set to announce its fourth quarter and fiscal year 2025 financial results on February 10, 2026. Following the release, a conference call will provide insights into the company's oncology advancements and future strategies.
January 11, 2026 Exelixis Inc. Reports Preliminary 2025 Financial Results and Outlines Ambitious 2026 Goals Exelixis, Inc. has announced its preliminary financial results for 2025, showing total revenues of approximately $2.320 billion. With ambitious goals for 2026, including the expansion of cabozantinib and the expected FDA approval for zanzalintinib, the company aims to strengthen its oncology portfolio and enhance shareholder value.
January 07, 2026 Exelixis and Natera Forge Partnership for Pivotal Colorectal Cancer Trial Exelixis and Natera have partnered to conduct the STELLAR-316 trial, which will assess the efficacy of zanzalintinib in colorectal cancer patients with molecular residual disease. This collaboration aims to improve treatment outcomes for high-risk patients and highlights the need for new therapeutic options in CRC.
January 06, 2026 Exelixis Inc. Set to Present at J.P. Morgan 2026 Healthcare Conference Exelixis Inc. will present at the J.P. Morgan 2026 Healthcare Conference on January 12, highlighting their oncology innovations and strategic direction. The company, known for CABOMETYX®, aims to enhance cancer treatment through its evolving product pipeline and research initiatives.
December 03, 2025 Exelixis Inc. Announces Virtual 2025 Research & Development Day Exelixis, Inc. will host its 2025 Research & Development Day virtually on December 10, highlighting advancements in oncology. The event will showcase the company's commitment to innovative cancer treatments and improving patient outcomes.
November 06, 2025 Exelixis Inc. Announces Upcoming Investor Conference Presentations Exelixis, Inc. is set to participate in two major investor conferences in November 2025, providing updates on their cancer treatment advancements. The company aims to engage stakeholders through informative fireside chats, highlighting their commitment to oncology innovation.
November 04, 2025 Exelixis Inc. Reports Robust Q3 2025 Results and Strategic Developments Exelixis, Inc. reported a robust financial performance with Q3 2025 revenues reaching $597.8 million, driven by its cabozantinib franchise. The company is focused on innovative cancer therapies and has exciting developments, including a drug application for zanzalintinib. Overall, Exelixis is well-positioned for future growth in the oncology market.
November 04, 2025 Exelixis Inc. Reports Strong Q3 2025 Financial Performance Amidst Competitive Landscape Exelixis, Inc. announced strong Q3 2025 financial results, with revenues up 12% and net income rising to $193.6 million. The company continues to innovate in oncology, focusing on expanding its product pipeline while managing costs effectively amidst competitive pressures.
October 21, 2025 Exelixis, Inc. to Announce Third Quarter Financial Results on November 4, 2025 Exelixis, Inc. is set to announce its third quarter financial results on November 4, 2025. Following the announcement, a conference call will provide insights into the company's oncology innovations and financial health, crucial for investors and stakeholders.
October 20, 2025 Exelixis Reports Promising Results from STELLAR-303 Trial for Metastatic Colorectal Cancer Exelixis reports promising findings from the STELLAR-303 trial, revealing that zanzalintinib combined with atezolizumab significantly improves overall survival for metastatic colorectal cancer patients. The results show a 20% reduction in the risk of death compared to standard treatment, highlighting a potential new therapy for this difficult-to-treat condition.
October 18, 2025 Exelixis Unveils Promising Data from CABINET Trial at ESMO 2025 Exelixis revealed promising data from the CABINET trial, highlighting CABOMETYX's effectiveness for advanced neuroendocrine tumors. The study showcased an 81% reduction in disease progression risk, with consistent safety findings. This breakthrough provides hope for patients with limited treatment options.
July 28, 2025 Exelixis Inc. Reports Q2 2025 Financial Results: A Mixed Bag of Growth and Challenges Exelixis, Inc. reported a mixed financial performance for Q2 2025, with product revenues increasing to $520 million but total revenues decreasing to $568.3 million. The company is focusing on expanding its product pipeline and navigating a challenging regulatory landscape while maintaining strong sales of its leading drug, cabozantinib.
May 13, 2025 Exelixis Reports Strong Q1 2025 Results and Provides Corporate Updates Exelixis, Inc. reported a revenue increase to $555.4 million for Q1 2025, driven by CABOMETYX sales. The company raised its full-year financial guidance, reflecting strong growth potential.
May 13, 2025 Exelixis Inc. Reports Strong Q1 2025 Results: A Positive Outlook Amidst Strategic Developments Exelixis, Inc. has reported strong Q1 2025 financial results, including $513.3 million in product revenues and a robust pipeline of oncology therapies. The company is well-positioned for future growth, driven by strong sales of CABOMETYX and strategic collaborations.
May 07, 2025 Exelixis Inc. Set to Engage Investors at Upcoming Conferences Exelixis, Inc. will participate in two significant investor conferences in May 2025, aiming to share insights on its oncology advancements. The company emphasizes its commitment to transparency and its mission to improve cancer treatment outcomes.
April 29, 2025 Exelixis Inc. Set to Release First Quarter 2025 Financial Results Exelixis, Inc. is set to release its financial results for Q1 2025 on May 13, 2025, followed by a conference call to discuss insights and future strategies. The company is a leader in oncology, focusing on innovative treatments like CABOMETYX® and ongoing research.
March 26, 2025 Exelixis Secures FDA Approval for CABOMETYX® in Neuroendocrine Tumors: A Game Changer for Patients Exelixis, Inc. has received FDA approval for CABOMETYX® to treat advanced neuroendocrine tumors in patients aged 12 and older. This breakthrough provides a new treatment option for patients facing poor prognoses and limited alternatives, bolstered by positive results from the CABINET trial.
March 25, 2025 Exelixis Inc. Showcases Promising Preclinical Data at AACR 2025 Exelixis Inc. is set to present preclinical data on four cancer treatment candidates at AACR 2025, highlighting advancements in innovative therapies. The data emphasizes their commitment to transforming cancer care through biotherapeutics and small molecules, with several candidates already advancing towards clinical trials.
February 25, 2025 Exelixis Inc. Set to Showcase Innovations at Upcoming Investor Conferences Exelixis, Inc. will host fireside chats at major investor conferences in March 2025 to discuss its oncology product pipeline and advancements in cancer care. These sessions will be accessible through live webcasts, with replays available for 30 days.
February 20, 2025 Exelixis Inc. Announces New $500 Million Stock Repurchase Program Exelixis, Inc. has announced a new $500 million stock repurchase program aimed at returning value to shareholders. This initiative follows a previous buyback program and illustrates the company's commitment to enhancing shareholder value while remaining focused on oncology innovation.
February 16, 2025 SWOT Analysis of Exelixis Inc. in 2025 This SWOT analysis of Exelixis Inc. in 2025 examines its strong product portfolio and innovative therapies, while also addressing risks related to dependence on CABOMETYX and competitive pressures. Opportunities for growth lie in new product development and strategic partnerships, essential for maintaining leadership in cancer therapeutics.
February 15, 2025 Exelixis Unveils Promising Long-Term Results for CABOMETYX® in Advanced Kidney Cancer Exelixis announces five-year results from the CheckMate-9ER trial, showcasing the efficacy of CABOMETYX combined with Opdivo in advanced kidney cancer. The study indicates significant improvements in progression-free and overall survival compared to standard treatments, with manageable safety profiles.
February 13, 2025 Exelixis Inc. to Engage in Critical Fireside Chat at Citi 2025 Virtual Oncology Leadership Summit Exelixis, Inc. will participate in the Citi 2025 Virtual Oncology Leadership Summit on February 19, 2025, offering insights into its strategic vision in oncology. The event will be accessible via a webcast, with a replay available for 30 days. Exelixis continues to lead in cancer treatment innovation.
February 11, 2025 Exelixis Inc. Reports Strong Financial Performance in 2024 Annual Report Exelixis Inc. reported strong financial performance in 2024, with total revenues of $2.17 billion, driven by CABOMETYX sales. The company also advanced its product pipeline and underwent corporate restructuring amid ongoing legal challenges.
February 11, 2025 Exelixis Inc. Reports Strong Financial Results for Fourth Quarter and Fiscal Year 2024 Exelixis Inc. reported a remarkable revenue growth for Q4 2024, totaling $566.8 million, fueled by strong cabozantinib sales. The company is poised for a promising 2025 with key clinical milestones on the horizon, aiming to enhance patient outcomes in oncology.
October 29, 2024 Exelixis Inc. Reports Strong Q3 2024 Results: A Financial Overview Exelixis Inc. has reported strong financial results for Q3 2024, with net revenues of $478.1 million and a significant increase in net income. The company is focusing on innovation through its product pipeline and strategic partnerships, positioning itself for continued growth in the oncology market.
August 06, 2024 Exelixis Inc. Reports Strong Q2 2024 Financial Results Amidst Strategic Developments Exelixis, Inc. reported impressive financial results for Q2 2024, with total revenues of $637.2 million and a net income increase to $226.1 million. The company is advancing its oncology pipeline, including pivotal trials for zanzalintinib and launching a Phase 1 trial for XB010, while also executing a significant stock repurchase program.
April 30, 2024 Exelixis Inc. Reports Q1 2024 Financial Results: A Steady Path Amid Restructuring Exelixis Inc. announced its Q1 2024 financial results, showcasing a 5% revenue increase driven by CABOMETYX sales despite overall revenue decline. The company is strategically reducing costs through restructuring while maintaining a strong cash position for future growth.
